AOD-9604 vs HGH Fragment 176-191: Fat Loss Peptides Compared

By the NorthPeptide Research Team — Updated January 2026

Origins: Where Both Peptides Come From

Both peptides are derived from the C-terminal region of human growth hormone (hGH). The fragment spanning amino acids 176–191 of the hGH sequence was identified as the region responsible for lipolytic (fat-burning) activity, separate from the growth-promoting effects mediated by IGF-1. This discovery prompted interest in isolating that activity in a standalone peptide.

• HGH Fragment 176-191: The raw amino acid sequence 176–191 of hGH
• AOD-9604: The same sequence with a tyrosine residue added at the N-terminus and a disulfide bridge stabilizing the structure — developed by Metabolic Pharmaceuticals (Australia)

Mechanism of Action

Both peptides work by mimicking the lipolytic domain of hGH without triggering the growth-promoting, IGF-1-mediated effects. The proposed mechanisms include:

• Beta-3 adrenergic receptor stimulation: Promoting fat cell breakdown (lipolysis), especially in visceral adipose tissue
• Inhibition of lipogenesis: Reducing the conversion of carbohydrates into fat
• No IGF-1 stimulation: Unlike full hGH, neither peptide appears to significantly raise IGF-1 levels in animal studies
• No effect on blood glucose: Both appear metabolically neutral with regard to insulin sensitivity in most studies

The Key Difference: Structure and Stability

AOD-9604’s added tyrosine residue and disulfide bridge confer structural changes that affect receptor binding kinetics and metabolic half-life. Some researchers theorize AOD-9604 has slightly improved tissue penetration and stability compared to the raw fragment, though direct head-to-head pharmacokinetic comparisons in humans are not available.

What the Research Shows

AOD-9604 Clinical Trials

AOD-9604 is one of the more clinically studied fat-loss peptides. Metabolic Pharmaceuticals ran Phase I, II, and III trials between the late 1990s and mid-2000s. Key findings:

• Phase II trials showed dose-dependent fat mass reduction vs. placebo over 12 weeks
• Phase III trials produced inconsistent results, with the primary endpoint (body weight reduction) not meeting statistical significance in all arms
• The FDA granted it GRAS (Generally Recognized As Safe) status as a food ingredient in 2014 — though this does not imply drug approval
• Safety profile appeared favorable across trials with no significant adverse events

HGH Fragment 176-191 Research

HGH Frag 176-191 has a smaller body of formal clinical research but a larger body of animal study data. Key findings from preclinical work:

• Obese rodents treated with HGH Frag 176-191 showed significant reductions in body fat compared to controls
• No changes in linear growth, suggesting IGF-1 pathways remain unactivated
• Some studies suggest effects on bone metabolism, with potential osteogenic (bone-building) properties

Research Applications: Which to Choose?

For researchers studying fat metabolism and metabolic regulation, the choice between the two depends on research goals:

• AOD-9604: Better choice when clinical-stage data is needed — it has the most robust safety record and human trial data of any GH-fragment peptide
• HGH Frag 176-191: Broader preclinical dataset, including bone metabolism and adipogenesis models
• Both: Useful for comparative studies on lipolysis without IGF-1 confounding variables

Research Products

Related Research Articles

PubMed Citations